Intensive Combination Approach to Rollback the Epidemic (iCARE) in Nigerian Adolescents
尼日利亚青少年抗击疫情的强化组合方法 (iCARE)
基本信息
- 批准号:10468148
- 负责人:
- 金额:$ 132.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-06 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAdolescentAdultAfrica South of the SaharaAgeAwarenessBloodCaringCenters for Disease Control and Prevention (U.S.)ClinicCollaborationsCommunitiesContinuity of Patient CareDevelopmentEpidemicEvidence based interventionFeedbackFocus GroupsGenderGoalsGovernmentHIVHIV InfectionsHIV SeroprevalenceHairHealthHot SpotHuman immunodeficiency virus testIncidenceInfrastructureInstitutionInterventionLinkLiteratureMeasurementMeasuresMediator of activation proteinMedical RecordsNigeriaNigerianOutcomeOutcome MeasurePersonsPharmacy facilityPhasePoliciesPopulationPovertyPrevalencePublic HealthRandomizedRecordsResearchResearch TrainingSiteSubgroupTestingText MessagingTimeUnited States National Institutes of HealthUniversitiesViralViral Load resultYouthagedantiretroviral therapybaseburden of illnesscare outcomesdesignevidence baseexperienceimprovedinnovationintervention effectmHealthmedication compliancemen who have sex with menmultidisciplinaryneglectpediatric human immunodeficiency virus infectionpeerpilot testpilot trialprimary outcomeprogramsresponsesame-sex partnershipsocial mediasocial stigmatherapy adherencetherapy developmenttransmission processworking groupyoung manyoung men who have sex with men
项目摘要
Nigeria has the 2nd highest number of people living with HIV (PLWH) and the most pediatric HIV infections
globally, however, it has been neglected as a focus of public health efforts. Progress towards UNAIDS 90-90-
90 goals in Nigeria has been slow with all goals < 35%. Youth and men who have sex with men (MSM), are the
weakest link in Nigeria's response to the HIV epidemic. Interventions reaching youth (including hard-to-reach
MSM) and improving HIV care outcomes across the HIV care continuum should involve combination
interventions as these have additive benefits compared to single interventions. In this study, we propose to
build on infrastructure developed through a very successful U.S-Nigeria HIV-centered academic partnership in
collaboration with partner institutions in Ibadan, Lagos and Jos, Nigeria. We will test two combination
interventions among youths aged 15 to 24 years across the HIV care continuum. In the UG3 phase, we will
(Aim 1) develop manualized interventions for: (a) HIV testing and linkage; and (b) HIV care outcomes among
youth age 15-24 years in Ibadan using a combination approach that includes theoretically-grounded peer
navigation and mHealth components. Once developed we will (Aim 2) test each combination intervention in
pilot trials in Ibadan for feasibility, acceptability and initial efficacy using a pre-post design. The two
interventions include: 2a) social media engagement + peer navigation to improve HIV testing and linkage to
care among young MSM. The pilot test for this intervention will be considered successful if there is an increase
of ≥ 30% in the number of young men completing HIV tests and an increase in the HIV incidence rate by
OR=2.0 over a 48-week period compared to baseline. In addition, we will pilot test: 2b) a short message
service (SMS; via adaptation of an evidence-based intervention, TXTXT) + peer navigation intervention to
improve HIV care outcomes (e.g. care retention, ART adherence and viral suppression) among 40 young
PLWH. This pilot intervention will be considered successful if there is ≥ 30% increase in proportion with viral
load < 1000 copies/mL over a 48-week period, reflecting an effect size of OR=1.5 compared to baseline. We
will also assess feasibility for measurement of medication adherence (via ART concentration in hair) and
retention in care (via medical records abstraction). In the UH3 phase we will (Aim 3) demonstrate the scalability
and efficacy of the two combination interventions in different HIV seroprevalence settings in Nigeria by: 3a)
conducting a randomized stepped wedge trial (5 steps, 6 sites) in Ibadan, Lagos and Jos; and 3b) testing ART
adherence and retention in care as mediators AND age, gender, and mode of transmission as potential
moderators of the HIV care intervention effect. We hypothesize that, using the same primary outcome
measures as in the UG3, the effect size of each combination intervention across and within settings, will be ≥
the effects observed in the UG3. Our goal is to develop efficacious and scalable combination intervention
strategies that will accelerate UNAIDS 90/90/90 goals among Nigerian youths, including MSM.
尼日利亚艾滋病毒感染者 (PLWH) 人数位居第二,儿童艾滋病毒感染人数最多
然而,在全球范围内,它作为公共卫生工作的重点却被忽视了,联合国艾滋病规划署 90-90- 的进展。
尼日利亚的 90 个进球进展缓慢,所有进球均低于 35%。
尼日利亚应对艾滋病毒流行的最薄弱环节 向青少年(包括难以接触到的青少年)提供的干预措施。
MSM)和改善整个艾滋病毒护理连续体的艾滋病毒护理结果应结合起来
干预措施,因为与单一干预措施相比,这些干预措施具有附加效益。
建立在通过非常成功的美国-尼日利亚以艾滋病毒为中心的学术伙伴关系开发的基础设施的基础上
与尼日利亚伊巴丹、拉各斯和乔斯的合作机构合作我们将测试两种组合。
在 UG3 阶段,我们将针对 15 至 24 岁青少年进行艾滋病毒护理连续性干预。
(目标 1)制定手动干预措施:(a) 艾滋病毒检测和联系;(b) 艾滋病毒护理结果;
伊巴丹 15-24 岁的青少年采用组合方法,其中包括基于理论的同龄人
一旦开发完成,我们将(目标 2)测试每种组合干预措施。
使用前后设计在伊巴丹进行了可行性、可接受性和初步功效的试点试验。
干预措施包括: 2a) 社交媒体参与 + 同伴导航,以改善艾滋病毒检测和与
如果有增加,则该干预措施的试点测试将被视为成功。
完成艾滋病毒检测的年轻男性人数≥30%,艾滋病毒发病率增加
与基线相比,48 周内 OR=2.0 此外,我们将进行试点测试:2b) 一条短信。
服务(短信;通过基于证据的干预措施的调整,TXXTT)+同伴导航干预
改善 40 名年轻人的艾滋病毒护理结果(例如护理保留、ART 依从性和病毒抑制)
如果病毒感染比例增加 ≥ 30%,则该试点干预措施将被视为成功。
48 周内负载量 < 1000 拷贝/mL,反映出与基线相比 OR=1.5 的效应大小。
还将评估测量药物依从性的可行性(通过头发中的 ART 浓度)和
在 UH3 阶段,我们将(目标 3)展示可扩展性。
两种联合干预措施在尼日利亚不同艾滋病毒血清流行情况下的效果:3a)
在伊巴丹、拉各斯和乔斯进行随机阶梯楔形试验(5 个步骤,6 个地点);3b) 测试 ART;
坚持和保留护理作为中介因素,年龄、性别和传播方式作为潜在因素
我们使用相同的主要结果来参与艾滋病毒护理干预效果的调节。
与 UG3 中的措施相同,跨环境和环境内每种组合干预的效果大小将 ≥
UG3 中观察到的效果我们的目标是开发有效且可扩展的组合干预措施。
将在尼日利亚青年(包括男男性行为者)中加速实施联合国艾滋病规划署 90/90/90 目标的战略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Babafemi O Taiwo其他文献
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial
吸入干扰素-β1a (SNG001) 在成人轻度至中度 COVID-19 中的安全性和有效性:一项随机、对照、II 期试验
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:15.1
- 作者:
P. Jagannathan;K. Chew;M. Giganti;Michael D. Hughes;C. Moser;Mark J. Main;P. D. Monk;A. Javan;Jonathan Z Li;Courtney V. Fletcher;Caitlyn McCarthy;David A Wohl;Eric S. Daar;Joseph J Eron;Judith Currier;Upinder Singh;Davey M. Smith;William A Fischer;K. Chew;David (Davey) Smith;Eric S. Daar;David A Wohl;Judith Currier;Joseph J Eron;Michael D. Hughes;M. Giganti;J. Ritz;L. Hosey;Jhoanna Roa;Nilam Patel;Kelly Colsh;Irene Rwakazina;Justine Beck;Scott F. Sieg;Jonathan Z Li;Courtney V. Fletcher;William A Fischer;Teresa H. Evering;Rachel Bender Ignacio;Sandra Cardoso;Katya Corado;N. Jilg;Alan S. Perelson;Sandy Pillay;C. Riviere;Babafemi O Taiwo;Jane Gottesman;M. Newell;Susan Pedersen;J. Dragavon;Cheryl Jennings;Brian Greenfelder;W. Murtaugh;Jan Kosmyna;Morgan Gapara;A. Shahkolahi;G. Pierone;Juliana Elliott;Jeffrey M. Jacobson;Leila Hojat;Julie Pasternak;Jonathan Berardi;Celine Arar;Yevgeniy Bukhman;Manish Jain;Eugene Bukhman;Sadia Shaik;T. Hatlen;Kelly Dooley;Becky Becker;Adaliah Wilkins;Jose Pérez;Eloy Roman;Heriberto Fernández;Keila Hoover;James Renfroe;Mauney Weldon;Genei Bougher;Carlos D. Malvestutto;Heather Harber;Robyn Cicarella;Gene Neytman;Jack Herman;Craig Herman;Mariam Aziz;Joan Swiatek;Divya Pathak;Madhu Choudhary;Jennifer Sullivano;O. Osiyemi;Myriam Izquierdo;Odelsey Torna;Aleen Khodabakhshian;Samantha Fortier;Constance A Benson;Steven Hendrickx;Rosemarie Ramirez;Anne Luetkemeyer;Suzanne Hendler;Dennis Dentoni;Mario Castro;L. Spikes;Chase Hall;Jonathan Oakes;A. Loftis;Pablo Tebas;William R Short;Sarah McGuffin;Chris Jonsson;Rachel Presti;Alem Haile - 通讯作者:
Alem Haile
Primary Human Immunodeficiency Virus
原发性人类免疫缺陷病毒
- DOI:
- 发表时间:
2002 - 期刊:
- 影响因子:0
- 作者:
Babafemi O Taiwo;Charles B. Hicks - 通讯作者:
Charles B. Hicks
Prevalence of depression among people living with HIV in rural hospitals in South-Western Nigeria-Association with clinico-demographic factors
尼日利亚西南部乡村医院艾滋病毒感染者抑郁症患病率与临床人口因素的关系
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:2.2
- 作者:
W. A. Adedeji;Qing Ma;Abiodun Muhammed Raji;Raymond Cha;Olaniran Mudasiru Rasaki;Alan Hutson;Babafemi O Taiwo;Man E Charurat;O. B. Yusuf;F. Fehintola;O. Gureje;Gene D. Morse - 通讯作者:
Gene D. Morse
Coincident rapid expansion of two SARS-CoV-2 lineages with enhanced infectivity in Nigeria
尼日利亚两个 SARS-CoV-2 谱系同时快速扩张,传染性增强
- DOI:
10.1101/2021.04.09.21255206 - 发表时间:
2021-04-17 - 期刊:
- 影响因子:0
- 作者:
E. Ozer;L. Simons;O. M. Adewumi;Adeola A Fowotade;E. Omoruyi;J. Adeniji;Taylor J Dean;Babafemi O Taiwo;J. Hultquist;R. Lorenzo - 通讯作者:
R. Lorenzo
Antiretroviral Therapy: Darunavir: An Overview of an HIV Protease Inhibitor Developed to Overcome Drug Resistance
抗逆转录病毒疗法:达芦那韦:为克服耐药性而开发的 HIV 蛋白酶抑制剂概述
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
Babafemi O Taiwo;Charles B. Hicks - 通讯作者:
Charles B. Hicks
Babafemi O Taiwo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Babafemi O Taiwo', 18)}}的其他基金
Expansion of SARS-CoV-2 Testing Supplement, Chicago Clinical Trials Unit
芝加哥临床试验中心 SARS-CoV-2 检测补充的扩展
- 批准号:
10166472 - 财政年份:2020
- 资助金额:
$ 132.16万 - 项目类别:
Intensive Combination Approach to Rollback the Epidemic (iCARE) in Nigerian Adolescents
尼日利亚青少年抗击疫情的强化组合方法 (iCARE)
- 批准号:
10228282 - 财政年份:2018
- 资助金额:
$ 132.16万 - 项目类别:
Intensive Combination Approach to Rollback the Epidemic (iCARE) in Nigerian Adolescents
尼日利亚青少年抗击疫情的强化组合方法 (iCARE)
- 批准号:
10600549 - 财政年份:2018
- 资助金额:
$ 132.16万 - 项目类别:
Intensive Combination Approach to Rollback the Epidemic (iCARE) in Nigerian Adolescents
尼日利亚青少年抗击疫情的强化组合方法 (iCARE)
- 批准号:
10252943 - 财政年份:2018
- 资助金额:
$ 132.16万 - 项目类别:
Expanded Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in Nigeria
扩大多学科神经艾滋病研究培训以改善尼日利亚的艾滋病毒治疗结果
- 批准号:
9903485 - 财政年份:2013
- 资助金额:
$ 132.16万 - 项目类别:
Expanded Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in Nigeria
扩大多学科神经艾滋病研究培训以改善尼日利亚的艾滋病毒治疗结果
- 批准号:
10462158 - 财政年份:2013
- 资助金额:
$ 132.16万 - 项目类别:
Expanded Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in Nigeria
扩大多学科神经艾滋病研究培训以改善尼日利亚的艾滋病毒治疗结果
- 批准号:
10349429 - 财政年份:2013
- 资助金额:
$ 132.16万 - 项目类别:
相似国自然基金
推拿“舒筋调骨”干预青少年脊柱侧弯“肌肉力学-椎间载荷”平衡机制研究
- 批准号:82374607
- 批准年份:2023
- 资助金额:51 万元
- 项目类别:面上项目
基于数字表型青少年自杀行为转化风险测度及虚拟现实矫正干预研究
- 批准号:72304244
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
青少年焦虑的预测和干预:基于跨通道恐惧泛化视角
- 批准号:32300928
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
心肺耐力对青少年执行功能影响效应及其特定脑区激活状态的多民族研究
- 批准号:82373595
- 批准年份:2023
- 资助金额:47 万元
- 项目类别:面上项目
视屏活动和CaMKII m6A甲基化修饰影响青少年抑郁症状的纵向研究
- 批准号:82304168
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN)Scientific Leadership Center; ADMIN SUPPLEMENT
艾滋病毒/艾滋病干预青少年医学试验网络 (ATN) 科学领导中心;
- 批准号:
10855435 - 财政年份:2023
- 资助金额:
$ 132.16万 - 项目类别:
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Scientific Leadership Center
艾滋病毒/艾滋病干预青少年医学试验网络 (ATN) 科学领导中心
- 批准号:
10595899 - 财政年份:2023
- 资助金额:
$ 132.16万 - 项目类别:
INTEGRATING A TRANSDIAGNOSTIC PSYCHOLOGICAL INTERVENTION IN THE CARE FOR ADOLESCENTS AND YOUTH WITH HIV IN KENYA
将跨诊断心理干预纳入肯尼亚艾滋病毒感染青少年的护理中
- 批准号:
10675988 - 财政年份:2023
- 资助金额:
$ 132.16万 - 项目类别:
Reducing the intersecting stigmas of HIV, violence victimization, and mental health: a randomized controlled pilot integrating Project YES! Youth Engaging for Success and Problem Management Plus amon
减少艾滋病毒、暴力受害和心理健康的交叉耻辱:整合“YES!”项目的随机对照试点
- 批准号:
10542948 - 财政年份:2022
- 资助金额:
$ 132.16万 - 项目类别: